Editorial Board

A. Seth
Editor-in-Chief
Laboratory of Molecular Pathology, Sunnybrook Research Institute, Sunnybrook Health Sciences Centre and University of Toronto, Toronto, Ontario, Canada

J.G. Delinassios
Managing Editor and Executive Publisher,
International Institute of Anticancer Research, Athens, Greece

L.A. Aaltonen
Department of Medical Genetics, University of Helsinki, Finland

S. Aaronson
Derald H. Ruttenberg Cancer Center, Mount Sinai School of Medicine, New York, NY, USA

R. Abagyan
The Scripps Research Institute, La Jolla, CA, USA

F. Ahmed
Department of Radiation Oncology, East Carolina University School of Medicine, Greenville, NC, USA

J.D. Aitchison
Institute for Systems Biology, Seattle, WA, USA

W. Ansorge
IAET, Borex, Switzerland

S. Antonarakis
Division of Medical Genetics, University of Geneva Medical School, Switzerland

F.G. Barr
Department of Pathology and Laboratory Medicine, University of Pennsylvania, Philadelphia, PA, USA

A.M. Burger
Barbara Ann Karmanos Cancer Institute, Wayne State University, Detroit, MI, USA

A.M. Chinnaian
Department of Pathology, University of Michigan Medical School, Ann Arbor, MI, USA

B.F.C. Clark
Department of Molecular Biology, University of Aarhus, Denmark

R. Clarke
Vincent T. Lombardi Cancer Center, Georgetown University School of Medicine, Washington, DC, USA

I. Dunham
The Wellcome Trust Sanger Centre, Wellcome Trust Genome Campus, Cambridge, UK

N.A. Ellis
Department of Medicine University of Chicago, IL, USA

J.A. Fernandes-Pol
Metalloproteomics, LLC, Chesterfield, MO, USA

C.V. Forst
McClintock Resource, Bioscience Division, Los Alamos National Laboratory, NM, USA

M. Fountoulakis
F. Hoffmann-La Roche Pharmaceutical Research, Basel, Switzerland

W.L. Gerald
Department of Pathology, Memorial Sloan-Kettering Cancer Center, New York, NY, USA

J.W. Gray
Cancer Genetics Program, Comprehensive Cancer Center, University of California San Francisco, CA, USA

B.B. Haab
Van Andel Research Institute, Grand Rapids, MI, USA

C.-H. Heldin
Ludwig Institute for Cancer Research, Uppsala, Sweden

J.D. Hoheisel
Deutsches Krebsforschungszentrum, Genome Research and Bioinformatics, Heidelberg, Germany

R.P. Huang
Department of Gynecology and Obstetrics, Emory University School of Medicine, Atlanta, GA, USA

T.H.M. Huang
Comprehensive Cancer Center, Human Cancer Genetics Program, Ohio State University, Columbus, OH, USA

Y. Ito
Institute of Molecular and Cell Biology, Oncology Research Institute, Yon Loo Lin School of Medicine, National University of Singapore, Singapore

V.C. Jordan
Fox Chase Cancer Center, Philadelphia, PA, USA

J. Ju
Translational Research Laboratories, State University of New York, School of Medicine, Stony Brook, NY, USA

A. Kallioniemi
Laboratory of Cancer Genetics, Institute of Medical Technology, Tampere University Hospital, Finland

O.P. Kallioniemi
Medical Biotechnology Group, VTT Technical Research Centre of Finland, Turku, Finland

M. Kanehisa
Kyoto University, Japan

S. Kottaridis
Department of Virology, Hellenic Anticancer Institute, Athens, Greece

B. Léyland-Jones
Winship Cancer Center, Emory University School of Medicine, Atlanta, GA, USA

P. Lichter
Deutsches Krebsforschungszentrum, Heidelberg, Germany

A. Lindblom
Karolinska Hospital, Department of Molecular Medicine and Surgery, Stockholm, Sweden

G. Lubec
Department of Pediatrics, University of Vienna, Austria

J. Lyons-Weiler
Department of Pathology, Center for Oncology Informatics, University of Pittsburgh, PA, USA

P.J. McCormick
The Center for Functional Genomics, Gen*NY*Sis Center for Excellence in Cancer Genomics, University of Albany, SUNY, Rensselaer, NY, USA

J.D. Minna
Hamon Center for Therapeutic Oncology, University of Texas, Southwestern Medical Center at Dallas, TX, USA

F. Mitelman
Department of Clinical Genetics, University Hospital, Lund, Sweden

P. Nelson
Fred Hutchinson Cancer Research Center, Seattle, WA, USA

C. Nicot
Department of Microbiology, Immunology and Molecular Genetics, University of Kansas Medical Center, Kansas City, KS, USA

L. O’Driscoll
School of Pharmacy and Pharmaceutical Sciences, Trinity College, Dublin, Ireland
Contents

MicroRNA-222 Regulates Cell Invasion by Targeting Matrix Metalloproteinase 1 (MMP1) and Manganese Superoxide Dismutase 2 (SOD2) in Tongue Squamous Cell Carcinoma Cell Lines. X. LIU, J. YU, L. JIANG, A. WANG, F. SH, H. YE, X. ZHOU (Chicago, IL, USA; Guangzhou, China) .......................................................... 131

Proteomic Analysis of Archival Breast Cancer Serum. B.A. ZEIDAN, R.I. CUTRESS, N. MURRAY, G.R. COULTON, C. HASTIE, G. PACKHAM, P.A. TOWNSEND (Southampton; Gosport; London; Portsmouth, UK) ....................... 141

Increased Levels of Macrophage-secreted Cathepsin S during Prostate Cancer Progression in TRAMP Mice and Patients. C. LINDAHL, M. SIMONSSON, A. BERGH, E. THYSELL, H. ANTTI, M. SUND, P. WIKSTRÖM (Umeå, Sweden) ...................................................................................................................................................... 149

Gene Expression Analysis of HCT116 Colon Tumor-derived Cells Treated with the Polyamine Analog PG-11047. N.A. IGNATENKO, H.F. YERUSHALMI, R. PANDEY, K.L. KACHEL, D.E. STRINGER, L.J. MARTON, E.W. GERNER (Haifa, Israel; Tucson, AZ; Redwood City, CA, USA) ........................................................................................................ 161

Diagnosis of Breast Cancer by Tear Proteomic Pattern. A. LEBRECHT, D. BOEHM, M. SCHMIDT, H. KOELBL, R.L. SCHWIRZ, F.H. GRUS (Mainz, Germany) ............................................................................................................................ 177


Gene Expression Profiling in Response to Estradiol and Genistein in Ovarian Cancer Cells. L.P. PARKER, D.D. TAYLOR, S. KESTERSON, C. GERCHEL-TAYLOR (Louisville, KY, USA) .................................................................................................................. 189
Instructions to Authors

General Policy. CANCER GENOMICS & PROTEOMICS (CGP) welcomes the submission of original high quality articles and reviews on the application of genomic and proteomic technology to experimental and clinical cancer research. The journal's topical spectrum includes: (a) Molecular causes of carcinogenesis, cancer progression and metastasis; (b) Structural and functional aspects of genes in the cancer cell; (c) Advances in genomic and proteomic technologies applicable to cancer research; (d) Rational anticancer drug design and drug development.

CGP will also accept abstracts and proceedings of scientific meetings for publication, following consideration and approval by the Editorial Board.

The principal aim of CGP is to provide for the prompt publication of original works of high quality, generally within 1-2 months of final acceptance. Manuscripts will be accepted with the understanding that they report original unpublished works that are not under consideration for publication by another journal, and that they will not be published again in the same form. All material submitted to CGP will be subject to review by two members of the Editorial Board and by one suitable outside referee. All manuscripts submitted to CGP are treated in confidence, without access to any person other that the Editor-in-Chief, the Managing Editor, the journal’s secretary, the reviewers and the printers. The Editors reserve the right to improve manuscripts on grammar and style. The Editors and Publishers of CGP accept no responsibility for the contents and opinions expressed by the contributors. Authors should warrant due diligence in the creation and issuance of their work.

NIH Open Access Policy. The journal acknowledges that authors of NIH funded research retain the right to provide a copy of the final manuscript to the NIH four months after publication in CGP, for public archiving in PubMed Central.

Copyright. Once a manuscript has been published in CGP, which is a copyrighted publication, the legal ownership of all published parts of the paper has passed from the Author(s) to the journal. Material published in the journal may not be reproduced or published elsewhere without written consent of the Managing Editor.

Format. Two types of papers may be submitted: (i) Full papers containing completed original work, and (ii) short papers. Additionally, the Editors may invite review articles concerning fields of recognisable progress. Papers should contain all essential data in order to make the presentation clear. Reasonable economy should be exercised with respect to the number of tables and illustrations used. Papers should be written in clear, concise English. Spelling should follow that given in the "Shorter Oxford English Dictionary".

Manuscripts. Submitted manuscripts should not exceed fourteen (14) pages (approximately 250 words per double - spaced typed page), including abstract, text, tables, figures, and references (corresponding to 4 printed pages). Papers exceeding four printed pages will be subject to excess page charges. All manuscripts should be divided into the following sections: (a) First page including the title of the presented work [not exceeding fifteen (15) words], full names and full postal addresses of all Authors, name of the Author to whom proofs are to be sent, key words, an abbreviated running title, an indication “clinical”, “epidemiological”, or “experimental” study, and the date of submission (Note: The order of the Authors is not necessarily indicative of their contribution to the work - Authors may note their individual contribution(s) in the appropriate section(s) of the presented work); (b) Abstract not exceeding 150 words, organized according to the following headings: Background/Aim - Materials and Methods/Patients and Methods - Results – Conclusion; (c) Introduction; (d) Materials and Methods/Patients and Methods; (e) Results; (f) Discussion; (g) Acknowledgements; (h) References. All pages must be numbered consecutively. Footnotes should be avoided. Review articles may follow a different style according to the subject matter and the Author's opinion. Review articles should not exceed 35 pages (approximately 250 words per double-spaced typed page) including all tables, figures, and references.

Figures. All figures (whether photographs or graphs) should be clear, high contrast, glossy prints of the size they are to appear in the journal: 8.00 cm (3.15 in.) wide for a single column; 17.00 cm (6.70 in.) for a double column; maximum height: 20.00 cm (7.87 in.). Graphs must be submitted as photographs made from drawings and must not require any artwork, typesetting, or size modifications. Symbols, numbering and lettering should be clearly legible. The number and top of each figure must be indicated on the reverse side. Original karyotypes and photographs should be provided wherever possible, and not photographic copies. Colour plates are charged.

Tables. Each table should be submitted on a separate page, typed double-spaced. Tables should be numbered with Roman numerals and should include a short title.

(HGNC) (http://www.gene.ucl.ac.uk/). Approved mouse nomenclature may be obtained from http://www.informatics.jax.org/. Standard abbreviations will be preferable. If a new abbreviation is used it must be defined at its first usage.

References. Citations for the reference sections of submitted works should follow the standard form of “Index Medicus” and must be numbered consecutively. In the text, references should be cited by number. Examples:


Ethical Policies and Standards. CGP agrees with and follows the “Uniform Requirements for Manuscripts Submitted to Biomedical Journals” established by the International Committee of Medical Journal Editors in 1978 and updated October 2001 (www.icmje.org). Microarray data analysis should comply with the “Minimum Information About Microarray Experiments (MIAME) standard”. Specific guidelines are provided at the “Microarray Gene Expression Data Society” (MGED) website. Presentation of genome sequences should follow the guidelines of the NHGRI Policy on Release of Human Genomic Sequence Data. Research involving human beings must adhere to the principles of the Declaration of Helsinki and Title 45, U.S. Code of Federal Regulations, Part 46, Protection of Human Subjects, effective December 13, 2001. Research involving animals must adhere to the Guiding Principles in the Care and Use of Animals approved by the Council of the American Physiological Society. The use of animals in biomedical research should be under the careful supervision of a person adequately trained in this field and at all times the animals must be treated humanely. Research involving the use of human fetuses, fetal tissue, embryos and embryonic cells should adhere to the U.S. Public Law 103-41, effective December 13, 2001.

Clinical Trials. Authors of manuscripts describing clinical trials should provide the appropriate clinical trial number in the correct format in the text. For International Standard Randomised Controlled Trials (ISRCTN) Registry (a not-for-profit organization whose registry is administered by Current Controlled Trials Ltd.) the unique number must be provided in this format: ISRCTNXXXXXXXX (where XXXXXXXX represents the unique number, always prefixed by ‘ISRCTN’). Please note that there is no space between the prefix ‘ISRCTN’ and the number. Example: ISRCTN47956475. For Clinicaltrials.gov registered trials, the unique number must be provided in this format: NCTXXXXXXXX (where XXXXXXXX represents the unique number, always prefixed by “NCT”). Please note that there is no space between the prefix “NCT” and the number. Example: NCT00001789.

Submission of Manuscripts. Follow the Instructions to Authors regarding the format of your manuscript and references. There are 3 ways to submit your article (NOTE: Please use only one of the below options - Do not send your articles twice):

1. To submit your article online please visit: IIAR-Submissions (http://www.iiar-anticancer.org/submissions/login.php)
2. You can send your article via e-mail to journals@iiar-anticancer.org (journals@iiar-anticancer.org). Please remember to always indicate the name of the journal you wish to submit your paper. The text should be sent as a Word document (“doc” link to attachment. Tables, figures and cover letter can also be sent as e-mail attachments.
3. You can send the manuscript of your article via regular mail in a USB stick, DVD, CD or floppy disk (including text, tables and figures) together with three hard copies of your manuscript to the following address:

John G. Delinassios, International Institute of Anticancer Research (IIAR), Editorial Office of ANTICANCER RESEARCH, IN VIVO, and CANCER GENOMICS & PROTEOMICS, 1st km Kapandritiou-Kalamou Road, P.O. Box 22, GR-19014 Kapandriti, Attiki, GREECE.

Submitted articles will not be returned to Authors upon rejection.

Galley Proofs. Unless otherwise indicated, galley proofs will be sent to the first-named Author of the submission. Corrections of galley proofs should be limited to typographical errors.

Reprints. Twenty-five copies of each communication will be provided free-of-charge. Additional copies or PDF files may be ordered after the acceptance of the paper. Requests for additional reprints and PDF files should be addressed to the Editorial Office.

Copyright © 2009, International Institute of Anticancer Research (Dr. John G. Delinassios). All rights reserved (including those of translation into other languages). No part of this journal may be reproduced, stored in a retrieval system, or transmitted in any form or by any means, electronic, mechanical, photocopying, microfilming, recording or otherwise without written permission from the Publisher.